(NASDAQ: GANX) Gain Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 4.12%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16%.
Gain Therapeutics's earnings in 2025 is -$18,593,064.On average, 4 Wall Street analysts forecast GANX's earnings for 2025 to be -$24,265,309, with the lowest GANX earnings forecast at -$25,164,024, and the highest GANX earnings forecast at -$23,366,594. On average, 3 Wall Street analysts forecast GANX's earnings for 2026 to be -$26,242,482, with the lowest GANX earnings forecast at -$29,477,857, and the highest GANX earnings forecast at -$20,131,219.
In 2027, GANX is forecast to generate -$37,386,550 in earnings, with the lowest earnings forecast at -$37,386,550 and the highest earnings forecast at -$37,386,550.